Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Shuji Ozaki, MD PhD, Takeshi Harada, MD PhD, Kengo Udaka, MD, Etsuko Sekimoto, MD PhD, Hironobu Shibata, MD PhD, Toshio Shigekiyo, MD PhD, Hikaru Yagi, MD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Masahiro Oura, MD, Shiro Fujii, MD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 5577.

https://doi.org/10.1182/blood-2018-99-115818

Published: 2018

Journal Articles

Anti-Myeloma Activity of the Maytansinoid Immunoconjugate of Internalizing Human Monoclonal Antibody Specific for HM1.24/BST2 (CD317).

Shuji Ozaki, Takafumi Tomura, Etsuko Sekimoto, Yoichi Tanaka, Kenichi Kitazoe, Jin Asano, Toshihiro Hashimoto, Masahiro Abe, Takayuki Furuta, Tomoyuki Tahara, Isao Ishida, Shiro Kataoka, Toshio Matsumoto

Blood (2005) 106 (11): 3388.

https://doi.org/10.1182/blood.V106.11.3388.3388

Published: 2005

Journal Articles

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2

Takashi Oshima, Masahiro Abe, Jin Asano, Tomoko Hara, Kenichi Kitazoe, Etsuko Sekimoto, Yoichi Tanaka, Hironobu Shibata, Toshihiro Hashimoto, Shuji Ozaki, Shinsuke Kido, Daisuke Inoue, Toshio Matsumoto

Blood (2005) 106 (9): 3160–3165.

https://doi.org/10.1182/blood-2004-12-4940

Published: 2005

Journal Articles

Human Monoclonal Antibodies to TRAIL Receptors R1 and R2 Effectively Induce Apoptosis in Human Myeloma Cells.

Shuji Ozaki, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Takashi Ohshima, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Kazuhiro Motoki, PhD, Isao Ishida, PhD, Shiro Kataoka, PhD, Toshio Matsumoto, MD

Blood (2004) 104 (11): 3366.

https://doi.org/10.1182/blood.V104.11.3366.3366

Published: 2004

Journal Articles

Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.

Takashi Oshima, MD, Masahiro Abe, MD, Jin Asano, MD, Tomoko Hara, MD, Kenichi Kitazoe, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Shinsuke Kido, MD, Daisuke Inoue, MD, Toshio Matsumoto, MD

Blood (2004) 104 (11): 2356.

https://doi.org/10.1182/blood.V104.11.2356.2356

Published: 2004

Journal Articles

Generation of HM1.24-Specific Cytotoxic T Lymphocytes from Peripheral Blood Stem Cell Harvests of Patients with Multiple Myeloma.

Ali Jalili, Shuji Ozaki, MD, Tomoko Hara, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Takashi Ohshima, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Yasuhiko Nishioka, MD, Toshio Matsumoto, MD

Blood (2004) 104 (11): 1487.

https://doi.org/10.1182/blood.V104.11.1487.1487

Published: 2004

NARROW

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Anti-Myeloma Activity of the Maytansinoid Immunoconjugate of Internalizing Human Monoclonal Antibody Specific for HM1.24/BST2 (CD317).

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2

Human Monoclonal Antibodies to TRAIL Receptors R1 and R2 Effectively Induce Apoptosis in Human Myeloma Cells.

Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.

Generation of HM1.24-Specific Cytotoxic T Lymphocytes from Peripheral Blood Stem Cell Harvests of Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Anti-Myeloma Activity of the Maytansinoid Immunoconjugate of Internalizing Human Monoclonal Antibody Specific for HM1.24/BST2 (CD317).

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2

Human Monoclonal Antibodies to TRAIL Receptors R1 and R2 Effectively Induce Apoptosis in Human Myeloma Cells.

Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.

Generation of HM1.24-Specific Cytotoxic T Lymphocytes from Peripheral Blood Stem Cell Harvests of Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only